We ensure you have support through regular follow-ups and adjustments for safe, effective weight loss
CDT This ADA-sponsored symposium will present Phase 3 results for retatrutide, an investigational once-weekly GIP, GLP-1, and glucagon triple receptor agonist, across two studies: TRIUMPH-1 : Retatrutide delivered powerful weight loss of up to an average of 70.3 lbs (28.3%) at 80 weeks in adults with obesity
On GLP-1, there is real human evidence: in a trial in people with metabolic syndrome, pasteurized Akkermansia muciniphila increased GLP-1 (Suenaert et al., 2026)
Mark the date clearly on the vial
In the world of recovery, inflammation control, and gut health, BPC-157 has gained a reputation as a powerhouse peptide
Yes, our skin whitening booster IV drip is perfectly safe when administered properly by qualified medical professionals at a licensed clinic